Characteristica | All Patients With PsA, N = 2315 | Biologic Initiators, N = 334 | ||
---|---|---|---|---|
Single Domainb, n = 617 | Multidomain, n = 1698 | Single Domainb, n = 45 | Multidomain, n = 289 | |
Enthesitis, n (%) | 11 (1.8) | 528 (31.1) | 2 (4.4) | 113 (39.1) |
SPARCC Enthesitis Index (1–16) | 2.1 (1.5) [11] | 3.8 (2.9) [528] | 1.5 (0.7) [2] | 3.6 (3.0) [113] |
Dactylitis, n (%) | 7 (1.1) | 228 (13.4) | 1 (2.2) | 69 (23.9) |
Dactylitis count (1–20) | 1.3 (0.5) [7] | 2.4 (2.1) [228] | 2.0 (NA) [1] | 2.5 (1.9) [69] |
Tender joint count (1–68) | 5.7 (6.9) [155] | 8.7 (10.2) [1226] | 6.8 (7.4) [20] | 9.1 (9.5) [240] |
Swollen joint count (1–66) | 4.0 (4.0) [127] | 4.8 (4.9) [966] | 4.5 (4.5) [18] | 6.2 (5.4) [199] |
Nail psoriasis VAS (1–100) | 13.3 (18.8) [67] | 19.1 (22.5) [975] | 26.0 (33.9) [2] | 27.3 (26.2) [157] |
DAPSA | 11.6 (10.1) [337] | 22.3 (17.5) [950] | 16.8 (13.0) [31] | 26.8 (19.2) [189] |
DAPSA group, n (%) | n = 337 | n = 950 | n = 31 | n = 189 |
Remission | 79 (23.4) | 53 (5.6) | 3 (9.7) | 6 (3.2) |
Low | 165 (49.0) | 292 (30.7) | 15 (48.4) | 44 (23.3) |
Moderate | 69 (20.5) | 359 (37.8) | 9 (29.0) | 69 (36.5) |
High | 24 (7.1) | 246 (25.9) | 4 (12.9) | 70 (37.0) |
PASDAS | 2.8 (1.2) [325] | 4.1 (1.4) [923] | 3.7 (1.0) [32] | 4.7 (1.4) [185] |
PASDAS group, n (%) | n = 325 | n = 923 | n = 32 | n = 185 |
Inactive | 198 (60.9) | 258 (28.0) | 9 (28.1) | 27 (14.6) |
Moderate | 80 (24.6) | 215 (23.3) | 12 (37.5) | 33 (17.8) |
Active | 45 (13.8) | 375 (40.6) | 10 (31.3) | 98 (53.0) |
Very active | 2 (0.6) | 75 (8.1) | 1 (3.1) | 27 (14.6) |
PGA (VAS 0–100) | 10.9 (15.0) [612] | 24.3 (21.4) [1686] | 22.6 (19.4) [45] | 36.4 (21.5) [287] |
PGA of psoriasis (VAS 0–100) | 12.9 (15.0) [594] | 28.0 (22.6) [1661] | 24.9 (20.6) [42] | 41.6 (22.0) [284] |
↵a All values were calculated based on available data and are presented as mean (SD) [n] unless otherwise stated; [n] represents the number of patients with data available.
↵b Single-domain disease presentations for PsA overall (N = 617) included skin disease (53.8%), peripheral arthritis (29.0%), nail psoriasis (10.9%), axial disease (3.4%), enthesitis (1.8%), and dactylitis (1.1%). Single-domain disease presentations for biologic initiators (N = 45) included peripheral arthritis (46.7%), skin disease (35.6%), axial disease (6.7%), nail psoriasis (4.4%), enthesitis (4.4%), and dactylitis (2.2%). DAPSA: Disease Activity in PSoriatic Arthritis; NA: not available; PASDAS: Psoriatic Arthritis Disease Activity Score; PGA: physician global assessment; PsA: psoriatic arthritis; SPARCC: Spondyloarthritis Research Consortium of Canada; VAS: visual analog scale.